Entreprises spin-off

Au PSI, les activités dans le domaine de la recherche et de la technologie ouvrent de multiples possibilités pour une exploitation commerciale. Lorsque ces technologies ou ces prestations de service tombent sur un scientifique qui a l'esprit d'entreprise, les conditions sont réunies pour une création d'entreprise.
Grâce au service de transfert de technologie et à différents outils de développement, le PSI soutient et encourage la création d'entreprises spin-off en offrant conseils et coaching.
Une entreprice spin-off du PSI est une nouvelle entreprise, fondée sur technologie et le savoir, élaboré à l'Institute Paul Scherrer dans le contèxte de ses activitées de recherche, quel que soit l'implication des collaborateurs du PSI.

XRnanotech

XRnanotech is a spin-off that develops and markets nanostructured diffractive optics. Such optical elements are used where conventional optics, e.g. made of glass, fail. They make it possible to record images with the highest resolution and thus make the smallest structures visible.
XRnanotech has managed to perfect the production of such nanostructured components and has been able to demonstrate unprecedented resolution in X-ray microscopy. This should lead to new insights in many areas of science and industry in the future. To this end, XRnanotech is already working with many international customers and marketing unique nanostructured optics.

Website: www.xrnanotech.com
Contact: Florian Döring, florian.doering@xrnanotech.com

Araris Biotech AG

Araris Biotech AG is a company focused on generating and developing so-called antibody-drug conjugates (ADCs). ADCs enable the delivery of highly-potent compounds precisely to certain cells (e.g. cancer cells) within the human body without harming healthy tissues. Araris has thereby discovered a new type of glue with which the drug can be rapidly and precisely attached onto the antibody without that they need to be engineered as today. Thanks to this glue pharma companies will not only save a lot of time and costs to generate these conjugates but they will also be very stable. Araris’ ADCs are expected to have an increase therapeutic efficiency with less side-effects.

Website: www.ararisbiotech.com
Contact: Philipp Spycher, pspycher@ararisbiotech.com

RADEC

RADEC utilizes high energy particles generated using particle accelerators located at PSI and elsewhere to test existing electronic components and materials for their resistance (hardness) to radiation. The company also offers advice and assistance to help their customers to develop and construct components and subsystems that are radiation hard. RADEC works together with companies involved in creating technologies for space, as well as companies developing terrestrial technology where failure due to radiation must be eliminated.

Website: www.radec.ch/
Contact: Radoslaw Marcin Marcinkowski, radec@radec.ch;

GratXray

GratXray’s vision is to provide all women painless, precise and efficient breast cancer imaging. For this, we develop a grating interferometry breast computed-tomography device (GI-BCT), a disruptive X-ray technology, which allows to simultaneously acquire absorption-, refraction- and scattering-based X-ray images. Those are capable of detecting subtle electron density variations and local small-angle scattering, generated by microscopic density fluctuations in the tissue, which yields to unprecedented lesion delineation and tissue discrimination.

Website: www.gratxray.com/
Contact: Dr. Martin Stauber, martin.stauber@gratxray.com;

novoMOF

novoMOF is a technology company in the field of advanced materials with focus on synthesis and production of metal-organic frameworks (MOF). MOFs are novel materials that offer competitive applications in various industrial sectors. For instance, charging times of batteries can be reduced to minutes, the lifetime of packaged food can be prolonged or gases such as carbon dioxide can be separated, purified or stored. We partner with leaders from different industries who want to exploit MOFs early as an innovation opportunity. We enable and shape this process early on by providing such companies access to custom MOFs based on their intended application.
Website: www.novoMOF.com
Contact: Daniel Steitz, daniel.steitz@novoMOF.com;

InterAx Biotech SA

InterAx is uniquely positioned to assist drug candidate design and selection by integrating bioanalytical and computational pharmacology in partnership projects with Biotech and Pharma companies. InterAx applies mathematical models and simulations to in house-derived bioanalytical data in order to address the complexity of drug-induced cellular signaling mechanisms. Our goal is to close the gap between laboratory experiments and in vivo studies by streamlining the critical processes of drug candidate design and selection, thereby significantly reducing the risks, costs and duration of drug discovery and development of new drugs.

Website: interaxbiotech.com
Contact: Luca Zenone, zenone@interaxbiotech.com

leadXpro AG

Website: www.leadXpro.com
Contact: Prof. Dr. Michael Hennig, Michael.Hennig@leadXpro.com

Advanced Accelerator Technologies AG

The aim of “Advanced Accelerator Technologies” (AAT) is to render PSI’s broad technological skills and expertise increasingly accessible on a global scale by joining forces with industrial companies that operate in the field of research equipment. The foundation of AAT with the theme complex Accelerators and Applied Technologies is simultaneously one of the four pillars of PARK innovAARE, which is being developed at PSI as part of the Swiss innovation park.

Site web: www.aa-t.ch
Contact: Dr. Jens Rehanek, jens.rehanek@aa-t.ch

4Quant

In the field of medical image analytics, we aim to disrupt the expensive, time-consuming, error-prone task of manually examining images by applying Big Data Analytics and Machine Learning. We scale the medical expertise of Radiologists by transforming their deep medical knowledge into robust algorithms. Analytics on vast amounts of images allows for significantly better biomarker detection in cohorts and time series, huge efficiency gains, as well as new research methods in clinical trials. Our office is located in Zurich. 4Quant was established as ETH/PSI spin-off in 2015 and has 3 employees.

Site web: www.4quant.com

Excelsus Structural Solutions

Excelsus Structural Solutions facilite et assure un accès abordable aux faisceaux de la Source Suisse de lumière de Synchrotron à haute intensité basée auprès de l’Institut Paul Scherrer. Avec une telle Source il est possible de mieux caractériser et de développer les produits pharmaceutiques dans le but de garantir une production de haute qualité.

Site web: www.excelsusss.com
Contact: Fabia Gozzo, Excelsus’CEO, Fabia.gozzo@excelsus2s.com

Expose GmbH

Expose propose des prestations de service dans le domaine de la cristallographie des protéines aux entreprises et aux organisations du secteur pharmaceutique et biotechnologique. L'entreprise organise les temps de mesure à la source de lumière suisse synchrotron (SLS) et effectue les analyses correspondantes. Cette offre est complétée par une assistance pour l'exploitation des données.

Site web: www.expose-crystals.com
Contact: diez@expose-crystals.com

SwissNeutronics AG

SwissNeutronics is the world-leading supplier of advanced neutron optics, which are an inevitable equipment for the scientific instrumentation at modern neutron research facilities. Key developments are the super-polishing of large area substrates (glass, silicone, metals) and their coating with thin film neutron supermirror (multilayer stack up to 10000 layers). As a result, the reflectivity of the supermirror is approaching the theoretical limits. The excellent supermirror, combined with sophisticated designs and high precision machining and assembly enable for first-class neutron optical devices. Moreover, SwissNeutronics owns a profound expertise in the neutronic and engineering design of neutron optics and of complete beam lines as well as for their installation. These capabilities are also provided to industry in Switzerland, beyond the field of neutron optics.

Site web: www.swissneutronics.ch
Contact: tech@swissneutronics.ch

DECTRIS AG

Au niveau mondial, DECTRIS est la première entreprise à proposer de nouveaux détecteurs de rayons X à pixels hybrides fonctionnant dans un mode qui compte chaque photon séparément. Cette nouvelle technologie se distingue par une très grande dynamique, un court temps de lecture et un excellent rapport signal/bruit. Ces propriétés améliorent considérablement la qualité de la mesure et le débit. Ils peuvent être utilisés dans différentes applications telles que les sources de lumière synchrotron, les systèmes de diffraction en laboratoire, ainsi que pour les applications industrielles et médicales des rayons X.

Site web: www.dectris.com

EULITHA AG

Dans la SLS du PSI, EULITHA produit des nanostructures périodiques extrêmement petites et denses avec une résolution inférieure à 20 nanomètres, et ce à l'aide de la lithographie par interférence d'EUV. Cette technologie productive peut, par exemple, être utilisée pour une production en série de disques durs ayant une capacité de stockage 100 fois supérieure à celle de l'état actuel de la technique, ou pour la production de nanostructures photoniques pour LED et écrans couleurs ou pour celle de nouveaux biosenseurs.

Site web: www.eulitha.com
Contact: Dr. Harun Solak, +41 56 310 4279, harun.solak@eulitha.com